15 years. While her diabetes was reasonably controlled using insulin pump therapy, controlling her grand mal seizures had always been difficult. Eventually, with a combination of levetiracetam and lamotrigine she had been free of seizures activity for over 2 years. However, this therapy resulted in severe daytime fatigue and a diagnosis of narcolepsy, which was initially treated with modafinil. However, because of the lack of efficacy of this drug, and the intolerable side effects caused by it, modafinil was replaced with GHB.
GHB was initiated at a dose of 2.25 g twice daily, with doses being administered before and after bedtime. The first morning after starting GHB at this dose, the fasting glucose exceeded 28 mmol/l and the hyperglycaemia was accompanied by moderate levels of urinary ketones. After multiple doses of fast-acting insulin delivered hourly from an insulin pump, the serum glucose dropped below 11 mmol/l and the ketonuria resolved. Over the next few days supplemental insulin was required. However, the need for supplemental insulin gradually waned over the first 5 days. After increasing the dose to 3 g and later to 3.75 g twice nightly there were similar elevations of serum glucose, which necessitated the use of multiple doses of fast-acting insulin, with the need for supplemental insulin, again gradually resolving over the subsequent 5 days.
I have reported a case of acute hyperglycaemia and ketosis, which could have resulted in diabetic ketoacidosis, induced by GHB in a type 1 diabetic patient. Therefore, the initiation of GHB therapy in the type 1 diabetic patient can transiently worsen glycaemic control to the point where hyperglycaemia is accompanied by ketosis. Why does this occur? It has been well documented that GHB can stimulate growth hormone and ACTH and cortisol release, which will induce resistance to the action of insulin [3] . It has also been shown that recreational use of GHB, presumably in high doses, can result in pseudoCushing's syndrome [4] . It is therefore likely that increased GHB levels result in upregulation of GHB receptors in the anterior pituitary gland, which results in elevated levels of both ACTH and growth hormone. Later, owing to adaptation to the increased GHB levels, there is downregulation of the anterior pituitary GHB receptors, and with each increase in the dose of GHB the receptors are again reactivated.
Endocrinologists, neurologists and other health professionals treating patients with type 1 diabetes should be aware that the initiation and advancement of GHB therapy is associated with worsening glycaemic control, and has the potential to induce ketosis or even ketoacidosis in the type 1 diabetic patient.
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